Healthcare resource use of patients with transthyretin amyloid cardiomyopathy-Reference-Cited by-同舟云学术

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

Published:2022-04 Issue:3 Volume:9 Page:1636-1642
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Lauppe Rosa¹^ORCID,Liseth Hansen Johan¹²,Fornwall Anna¹,Johansson Katarina³,Rozenbaum Mark H.⁴,Strand Anne Mette⁵,Vakevainen Merja⁶,Kuusisto Johanna⁷,Gude Einar⁸,Smith J. Gustav⁹¹⁰,Gustafsson Finn¹¹

Affiliation:

1. Quantify Research AB Stockholm 112 21 Sweden

2. Institute of Health and Society, Faculty of Medicine University of Oslo Oslo Norway

3. Pfizer AB Stockholm Sweden

4. Pfizer, Inc. Capelle aan den IJssel The Netherlands

5. Pfizer Denmark ApS Ballerup Denmark

6. Pfizer Oy Helsinki Finland

7. Department of Medicine and Clinical Research Kuopio University Hospital and University of Eastern Finland Kuopio Finland

8. Department of Cardiology Oslo University Hospital Rikshospitalet Oslo Norway

9. Department of Cardiology, Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Clinical Sciences Lund University and Skåne University Hospital Lund Sweden

10. The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine Gothenburg University and Sahlgrenska University Hospital Gothenburg Sweden

11. Department of Cardiology Rigshospitalet Copenhagen Denmark

Funder

Pfizer

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13913

Reference22 articles.

1. Advances in the Treatment of Cardiac Amyloidosis

2. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice